Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

NCT ID: NCT05289167

Last Updated: 2024-12-27

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 74 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-13
• Study Completion Date: 2027-12-31

Brief Summary

This is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.

Detailed Description

The study will have a phase I and phase II potions. The phase I portion will employ a 3+3 dose escalation design to define the maximum tolerated dose (MTD) of abatacept added to PTCy and bortezomib following HSCT. The phase II portion will consist of two single arm, open label, optimal 2-stage Simon design studies conducted in two separate strata for HLA matched and HLA mismatched donor transplants. Adult patients with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the standard criteria defined in our institutional standard operation procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria. Subjects will receive a standard of care conditioning regimen followed by peripheral blood hematopoietic stem cells. Subjects with unrelated donors will also receive rabbit anti-thymocyte globulin (rATG). Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis. The phase II portion dose of abatacept will be the MTD as determined in the phase I portion of the study. In the phase II portions, subjects will be stratified based on whether they receive a matched sibling or matched unrelated (matched) donor transplant and ≥7 out of 8, allele level matched (mismatched) unrelated donor transplant.

Conditions

Graft-versus-host Disease

Keywords

GvHD, post transplant cyclophosphamide, abatacept

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Participants with hematological malignancies

Participants undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will receive a combination of cyclophosphamide, known commercially as Cytoxan®, abatacept, known as Orecia® and bortezomib commercially known as Velcade®, to reduce the rate of graft-versus-host disease (GvHD). These medications will be given for GvHD prevention during the transplant process.

Group Type: EXPERIMENTAL

Cyclophosphamide

Intervention Type: DRUG

50 mg/kg IV over 1 hour on Day +3 and +4

Abatacept

Intervention Type: DRUG

Dose level 0: 10 mg/kg IV over 30 minutes on day +5

Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14

Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28

Bortezomib

Intervention Type: DRUG

1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.

Interventions

Cyclophosphamide

50 mg/kg IV over 1 hour on Day +3 and +4

Intervention Type: DRUG

Abatacept

Dose level 0: 10 mg/kg IV over 30 minutes on day +5

Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14

Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28

Intervention Type: DRUG

Bortezomib

1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.

Intervention Type: DRUG

Other Intervention Names

Cytoxan®; Orecia®; Velcade®

Eligibility Criteria

Inclusion Criteria

• Age ≥18 years
• Karnofsky score ≥70%
• No evidence of progressive bacterial, viral, or fungal infection
• Creatinine clearance >50 mL/min/1.72m2
• ALT and AST <3 x the upper limit of normal
• Total bilirubin <2 x the upper limit of normal (except for Gilbert's syndrome)
• Alkaline phosphatase ≤250 IU/L
• Left Ventricular Ejection Fraction (LVEF) >45%
• Adjusted Carbon Monoxide Diffusing Capacity (DLCO) >50%
• Negative HIV serology
• Negative pregnancy test: Confirmation per negative serum β-human chorionic gonadotropin (β-hCG)
• Willing to comply with all study procedures and be available for the duration of the study.

Exclusion Criteria

• Pregnant or nursing females or women of reproductive capability who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of contraception from start of conditioning through 90 days after the last dose of study drug. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post-menopausal (stopped menstrual periods) for more than 24 months in a row.
• Male subjects who refuse to practice effective barrier contraception from the start of conditioning through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post-vasectomy).
• Inability to provide informed consent.
• Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see Appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
• Known allergies to any of the components of the investigational treatment regimen.
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
• Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy.
• Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial.
• Prisoners
• Pregnant women

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Northwell Health

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

A. Samer Al-Homsi, MD, MBA

Role: PRINCIPAL_INVESTIGATOR

Northwell Health

Locations

Northwell Health

New Hyde Park, New York, United States

Countries

United States

Other Identifiers

21-00797

Identifier Type: -

Identifier Source: org_study_id